What is ETNA and how can it revolutionize current MS assessment?

Innodem Neurosciences, a leader in innovation and technology, has received the "Breakthrough Device" designation from the U.S. Food & Drug Administration. The innovation enables eye-tracking neurological assessment for multiple sclerosis. It records eye movements to accurately estimate the disease's severity in patients. This innovation will revolutionize current uses, which have been in use for decades, and will allow clinicians to monitor the progression of the disease. In addition, this app-based technology is user-friendly, turning a tablet into a state-of-the-art device that can accurately capture eye movements and map biomarkers in minutes. The results will allow clinicians to be informed remotely about the patient's disease status and progression and thus adapt their treatment.

Why monitor the eyes?

The scientific literature shows that eye movement can serve as powerful markers of brain health, especially in MS. However, current onboard equipment is complex to use, expensive and the data difficult to analyze, making it difficult for clinicians to benefit from it. EMBs/GMBs can detect subtle motor and cognitive function changes found in MS progression but are difficult or impossible to quantify with routine neurological exams or conventional brain imaging (MRI). To date, with the current standard treatment of MS, it usually takes several years before clinicians can establish the presence of disease progression. However, this revolutionary application makes regular and more frequent monitoring possible, allowing the clinician to initiate or adjust appropriate treatment.